Literature DB >> 1585913

Acquired von Willebrand disease: correction of hemostatic defect by high-dose intravenous immunoglobulins.

A Delmer1, M H Horellou, J M Bréchot, J Prudent, F Potevin, C Lecrubier, C Girard-Longhini, M Samama, R Zittoun.   

Abstract

High-dose intravenous immunoglobulins (ivIG) were used in a 57-year-old patient with acquired von Willebrand disease in order to correct a hemostatic defect before pneumonectomy for lung carcinoma. IvIG induced a rapid and complete correction of factor VIII (F VIII) and von Willebrand factor (vWF) and allowed surgery without additional factor coverage. F VIII and vWF returned to baseline values within 10 days after ivIG.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1585913     DOI： 10.1002/ajh.2830400214

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  6 in total

Review 1.  Intravenous immunoglobulin therapy for acquired coagulation inhibitors: a critical review.

Authors:  Koji Yamamoto; Junki Takamatsu; Hidehiko Saito
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

2.  Acquired von Willebrand's disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland.

Authors:  Geoffrey Spencer Chilvers; Graham Porter
Journal:  BMJ Case Rep       Date:  2014-08-05

Review 3.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 4.  Current management of von Willebrand's disease.

Authors:  G Castaman; F Rodeghiero
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 5.  High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease.

Authors:  P J Van Genderen; D N Papatsonis; J J Michiels; J J Wielenga; J Stibbe; F J Huikeshoven
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

Review 6.  The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.

Authors:  Chanukya K Colonne; Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Healthcare (Basel)       Date:  2022-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.